Insight Molecular Diagnostics (IMDX) risk factors
Item 1A of every Insight Molecular Diagnostics Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors51 risks7 new4 dropped9 reworded
Net losses narrowed to $50.2 million in 2025 from $60.7 million in 2024, with accumulated deficit reaching $400.8 million. Research and development expenses increased to $15.9 million as clinical trials for GraftAssureDx began. FDA enforcement discretion rules for LDTs experienced regulatory shifts and legal challenges.
Filed Mar 26, 2026 - FY2024 10-K risk factors48 risks
Company faces substantial operating losses and an accumulated deficit of $350.5 million as of December 31, 2024. Operations depend heavily on commercializing a small group of diagnostic tests including GraftAssureCore and DetermaIO. Revenues rely heavily on third-party payer coverage, Medicare billing policies, and FDA regulatory determinations for LDTs versus IVDs.
Filed Mar 24, 2025